腫瘍診断における PET の現状と進歩

18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has repidly entered into widespread use throughout Japan. Over 200 PET centers are currently in use. FDG-PET can be used to detect many malignant tumors and has become the gold standard for oncologic imaging. However, many false-negative cases have been reported. Many new radiopharmaceuticals have been developed as post-FDG agents. One of these radiopharmaceuticals, 11C- acetate (AC), has been used to detect tumors for which FDG gives poor results. The usefulness of AC-PET remains to be established, but many reports have suggested its utility for tumors, such as prostate cancer, lung cancer, hepatocellular carcinoma, brain glioma. etc.